Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2004-04-08

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00080925

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Biological: oblimersen sodium
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT00080847

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-04-06

Last Posted Date: 2013-05-15

Lead Sponsor: Stanford University

Registration Number: NCT00002714

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: mesna
Drug: methotrexate
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-04-06

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 134

Registration Number: NCT00002494

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

and more 20 locations

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Small Intestine Cancer

First Posted Date: 2004-03-10

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 25

Registration Number: NCT00079261

Locations: 🇭🇷
University Hospital Rebro, Zagreb, Croatia
🇳🇱
Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands
🇧🇪
Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium

and more 3 locations

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: prednisone
Drug: thalidomide

First Posted Date: 2004-03-08

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 67

Registration Number: NCT00006890

Locations: 🇺🇸
St. Mary's/Duluth Clinic Health System, Duluth, Minnesota, United States
🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada

and more 61 locations

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

Phase 3

Withdrawn

Conditions: Leukemia

First Posted Date: 2004-02-27

Last Posted Date: 2012-03-23

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00019409

Locations: 🇮🇳
Tata Memorial Centre, Mumbai, India
🇮🇳
Cancer Institute (W.I.A.), Madras, India
🇮🇳
All-India Institute of Medical Sciences, New Delhi, India

and more 3 locations

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

Phase 3

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-02-26

Last Posted Date: 2013-12-18

Lead Sponsor: Medsearch

Registration Number: NCT00014339

Locations: 🇺🇸
Southwest Cancer Care, Poway, California, United States
🇺🇸
West Clinic, P.C., Memphis, Tennessee, United States
🇺🇸
Oncology-Hematology Associates, P.A., Clinton, Maryland, United States

and more 16 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-02-16

Last Posted Date: 2013-06-21

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 630

Registration Number: NCT00003150

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States

and more 88 locations

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-02-16

Last Posted Date: 2017-01-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 71

Registration Number: NCT00005089

Locations: 🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 89 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy